Targeting Hepatic Stellate cells in MASH

Targeting hepatic stellate cells (HSCs) in metabolic dysfunction-associated steatohepatitis (MASH) represents a promising therapeutic approach to prevent or reverse liver fibrosis, a key driver of disease progression. Below is a detailed explanation of the context, mechanisms, and therapeutic strategies derived from the study:

### 1. **Role of Hepatic Stellate Cells in Fibrosis**:

• **HSC Activation**: In healthy livers, HSCs exist in a quiescent state (Q), storing vitamin A and maintaining normal extracellular matrix (ECM) turnover. However, in MASH, chronic liver injury caused by metabolic dysfunction (e.g., lipotoxicity, inflammation) triggers HSC transdifferentiation into activated myofibroblast-like cells.
• **Fibrogenic Myofibroblasts**: Once activated, HSCs (A1 and A2 phenotypes) proliferate and secrete fibrotic ECM components like collagen and fibronectin. This excessive ECM deposition leads to liver scarring (fibrosis), which impairs liver function and contributes to disease progression.

### 2. **Key Findings from the Study**:

• **HSC Subpopulations**: The study identified four distinct HSC phenotypes—quiescent (Q), activated (A1 and A2), and inflammatory (INF). Activated HSCs (A1 and A2) were found to dominate in MASH livers, constituting 13–20% of total liver cells compared to only 4–8% in normal livers.
• **Core Fibrogenic Genes**: Six genes—**SERPINE1, GAS7, SPON1, LTBP2, KLF9, and EFEMP1**—were identified as a core fibrogenic gene set driving HSC activation and fibrosis. These genes were upregulated and showed enhanced chromatin accessibility in activated HSCs.
• **Pathway Enrichment**: These genes are involved in ECM organization and actin filament regulation, essential for fibrotic scar formation and HSC activation.
• **RUNX1/2–SERPINE1 Axis**: The study discovered that the **RUNX1/2-SERPINE1 signaling axis** is a pivotal regulatory pathway promoting HSC activation and ECM deposition, making it a key therapeutic target.

### 3. **Therapeutic Strategies for Targeting HSCs**:

• **Targeting SERPINE1 (PAI-1)**:
• SERPINE1 encodes plasminogen activator inhibitor-1 (PAI-1), a protein that promotes ECM accumulation and fibrosis.
• **Knockdown of SERPINE1** in 3D human MASH liver spheroid models using dicer-substrate siRNA (dsiRNA) significantly reduced fibrogenic marker expression (e.g., COL1A1, ACTA2, TIMP1).
• In **in vivo mouse models**, genetic deletion or pharmacologic inhibition of PAI-1 protected against fibrosis induced by liver injury (e.g., CCl₄ or a western diet).
• Blocking PAI-1 also inhibited TGFβ-driven fibrotic signaling, suggesting its potential as a therapeutic target.
• **Targeting SPON1 and LTBP2**:
• Silencing SPON1 and LTBP2 suppressed TGFβ signaling and ECM protein expression, confirming their roles in HSC activation and fibrogenesis.
• **Epigenetic Modulation**:
• Chromatin accessibility correlated strongly with the activation of fibrogenic genes. Targeting epigenetic regulators that maintain open chromatin at fibrogenic gene loci could prevent HSC activation.
• **Transcription Factor Inhibition**:
• The study highlighted three classes of transcription factors (TFs) regulating HSC activation:
• **Lineage-specific TFs**: JUNB/AP-1.
• **Cluster-specific TFs**: RUNX1/2.
• **Signal-specific TFs**: FOXA1/2.
• Disrupting the crosstalk between RUNX1/2 and FOXA1/2 could block the integration of mechanical (ECM) and cytokine (TGFβ) signals into fibrogenic transcriptional outputs.
• **TGFβ Pathway Inhibition**:
• TGFβ signaling is a major driver of HSC activation and fibrosis. Therapeutics targeting TGFβ signaling (e.g., inhibitors of TGFβ receptors or downstream effectors) could effectively reduce fibrosis.

### 4. **Validation of Therapeutic Targets**:

• **Functional Validation**:
• Knockdown of SERPINE1 in human MASH liver spheroids reduced fibrogenic markers, demonstrating its functional role in fibrosis.
• **In Vivo Validation**:
• In mouse models, genetic deletion or pharmacologic inhibition of PAI-1 prevented fibrosis under various liver injury conditions.
• **Cross-Species Validation**:
• The identified HSC subclusters and fibrogenic signatures in humans were closely mirrored in murine MASH models, highlighting the translational relevance of these findings.

### 5. **Mechanistic Insights**:

• **Epigenetic Priming**:
• Activation-associated genes in HSCs were epigenetically primed through open chromatin in promoter and enhancer regions, enabling rapid transcriptional responses to fibrogenic signals.
• **Transcriptional Pseudotime Analysis**:
• Trajectory analysis revealed a stepwise progression of HSCs from quiescent (Q) to activated states (A1 → A2), with the gradual acquisition of fibrogenic gene signatures.
• **RUNX1/2 and FOXA1/2 Crosstalk**:
• Mechanistic modeling suggested direct interaction between RUNX1/2 and FOXA1/2, integrating ECM and cytokine signals into fibrogenic transcriptional outputs.

### 6. **Therapeutic Potential**:

• The study underscores the potential of targeting the RUNX1/2–SERPINE1 axis or downstream fibrogenic genes (e.g., SPON1, LTBP2, GAS7) as antifibrotic strategies in MASH.
• By combining transcriptomic, epigenomic, and functional assays, the study provided a comprehensive understanding of HSC activation dynamics and identified concrete druggable pathways.

### 7. **Conclusion**:

• Targeting hepatic stellate cells in MASH offers a promising therapeutic strategy to combat liver fibrosis. The identification of key regulatory pathways (e.g., RUNX1/2–SERPINE1 axis) and fibrogenic genes (e.g., SPON1, LTBP2) provides a solid foundation for developing antifibrotic therapies.
• Future therapies could involve small-molecule inhibitors, RNA-based therapeutics (e.g., siRNA), or monoclonal antibodies targeting these pathways to prevent or reverse fibrosis in metabolic liver disease.